Literature DB >> 33385181

Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome.

Dongmei Yin1,2, Philip G de Groot2, Marisa Ninivaggi2, Katrien M J Devreese3,4, Bas de Laat1,2.   

Abstract

BACKGROUND: Patients positive for all three types of antiphospholipid antibodies (aPLs; triple positivity) have been identified for having a high risk for thrombotic events. However, the clinical significance of isolated lupus anticoagulant (LAC) positivity is debated.
OBJECTIVES: To investigate the clinical relevance of isolated LAC.
METHODS: A total of 456 patients were enrolled in this study; 66 antiphospholipid syndrome patients and 390 control patients. The control group consisted of autoimmune patients (n = 91), patients with thrombosis but without aPLs (n = 127), and normal controls (n = 172). LAC, anticardiolipin (anti-CL), and anti-β2 glycoprotein I (anti-β2GPI) immunoglobulin G (IgG) and immunoglobulin M (IgM) were determined according to the International Society on Thrombosis and Haemostasis (ISTH) guidelines. Anti-CL and anti-β2GPI were measured by four different solid-phase platforms to overcome variability between test systems. The noncriteria IgA anti-CL and anti-β2GPI, antidomain I of β2GPI IgG, and antiphosphatidylserine/prothrombin antibodies (anti-PS/PT) IgG and IgM were detected according to the ISTH guidelines for solid-phase assays.
RESULTS: In total, 70 patients were positive for LAC, of which 44 were negative for both anti-β2GPI and anti-CL antibodies. We found that isolated LAC proved to be strongly associated with vascular thrombosis (odds ratio [OR]: 7.3; 95% confidence interval [CI]: 3.3-16.1), even better than triple-positive samples (OR: 4.3; 95% CI: 1.6-12.2). The titers of the anti-PS/PT IgG and IgM were significantly higher in triple-positivity samples compared with samples with isolated LAC positivity. The majority of single LAC positives were anti-PS/PT-negative. We observed that LAC positivity was weaker in isolated LAC-positive patients compared with LAC activity in triple-positive patients.
CONCLUSION: Isolated LAC was highly associated with thrombosis. The presence of anti-PS/PT antibodies could not explain LAC positivity in isolated LAC. Isolated LAC showed a weaker LAC activity compared with triple-positive patients. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33385181     DOI: 10.1055/a-1344-4271

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   6.681


  4 in total

1.  Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository.

Authors:  Erivelton de Azevedo Lopes; Gustavo Guimarães Moreira Balbi; Maria G Tektonidou; Vittorio Pengo; Savino Sciascia; Amaia Ugarte; H Michael Belmont; Maria Gerosa; Paul R Fortin; Chary Lopez-Pedrera; Lanlan Ji; Hannah Cohen; Guilherme Ramires de Jesús; D Ware Branch; Cecilia Nalli; Michelle Petri; Esther Rodriguez; Nina Kello; Roberto Ríos-Garcés; Jason S Knight; Tatsuya Atsumi; Rohan Willis; Maria Laura Bertolaccini; Doruk Erkan; Danieli Andrade
Journal:  Adv Rheumatol       Date:  2021-10-28

Review 2.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

3.  Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome.

Authors:  Katrien M J Devreese; Stéphane Zuily; Pier Luigi Meroni
Journal:  J Transl Autoimmun       Date:  2021-11-06

4.  Sex Differences in Clinical Characteristics and Prognosis in Primary Thrombotic Antiphospholipid Syndrome.

Authors:  Yongfa Huang; Huazhen Liu; Wanting Qi; Le Du; Mengtao Li; Xiaofeng Zeng; Xiaoxiao Guo; Jiuliang Zhao; Shuyang Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.